HLA-G and metastatic colorectal cancer: In metastatic colorectal cancer, irinotecan could be captured by HLA-G proteins, resulting in changes in pharmacokinetics and interference with the interaction between HLA-G and its receptor, but it remains ambiguous whether anti-HLA-G therapies could potentiate or attenuate the efficacy of irinotecan [140].